The Food and Drug Administration (FDA) has approved Duavee, Pfizer’s new hormone treatment for menopause-related hot flashes in women who have not had a hysterectomy, and to prevent osteoporosis in post-menopausal women. Duavee is the first FDA-approved drug that combines a mixture of estrogens with another compound, bazedoxifene, which acts like estrogen to protect bone density. The FDA rejected bazedoxifene as an osteoporosis treatment in 2009 after numerous delays based on concerns that the drug could increase the risk for strokes and blood clots. Duavee enters a profitable market that already includes Hisamitsu Pharmaceutical Co.’s Brisdelle and Eli Lilly & ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.